Core Viewpoint - The company, Nengte Technology (002102.SZ), has announced a share buyback program, having repurchased a total of 34.2361 million shares, which represents 1.38% of its total share capital, with a total transaction amount of 140 million yuan (excluding transaction fees) [1] Summary by Categories Share Buyback - The company has completed a cumulative buyback of 34.2361 million shares as of October 31, 2025 [1] - This buyback accounts for 1.38% of the company's total share capital [1] - The total amount spent on the buyback is 140 million yuan, excluding transaction fees [1]

Core Viewpoint - The company, Nengte Technology (002102.SZ), announced a share buyback plan, having repurchased a total of 34.2361 million shares, which represents 1.38% of its total share capital, with a total transaction amount of 140 million yuan (excluding transaction fees) [1] Summary by Relevant Categories Share Buyback - The company has completed a cumulative buyback of 34.2361 million shares as of October 31, 2025 [1] - This buyback accounts for 1.38% of the company's total share capital [1] - The total amount spent on the buyback is 140 million yuan, excluding transaction fees [1]

Group 1 - The company, Nengte Technology, announced on November 3 that it has repurchased approximately 34.24 million shares through a dedicated securities account, accounting for 1.38% of its total share capital of approximately 2.476 billion shares [1] - The highest transaction price for the repurchased shares was 4.39 CNY per share, while the lowest was 3.97 CNY per share [1] - The total amount spent on the share repurchase was approximately 140 million CNY [1]

证券代码：002102 证券简称：能特科技 公告编号：2025-102 湖北能特科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 湖北能特科技股份有限公司（以下简称"公司"）于 2025 年 7 月 2 日召开 了第七届董事会第三十三次会议、第七届监事会第二十六次会议，于 2025 年 7 月 18 日召开了 2025 年第五次临时股东大会，审议通过了《关于回购股份并注销 的议案》，同意公司使用自有资金及自筹资金以资金总额不低于人民币 30,000 万元（含），不超过人民币 50,000 万元（含），回购价格不超过人民币 4.70 元/ 股（含），通过深圳证券交易所交易系统以集中竞价交易方式回购部分公司股份， 实施期限为自公司股东大会审议通过回购方案之日起 12 个月内（即 2025 年 7 月 19 日至 2026 年 7 月 18 日），具体回购股份的数量以回购方案实施完毕时实 际回购的股份数量为准。本次回购股份将全部用于注销并相应减少注册资本。具 体内容详见公司于 2025 年 7 月 19 日披露的《回购报 ...

Core Insights - Nengte Technology, established in September 2002 and listed in December 2006, is a leading domestic producer of pharmaceutical intermediates and Vitamin E, showcasing significant investment value [1] Group 1: Business Performance - For Q3 2025, Nengte Technology reported revenue of 7.13 billion, ranking second among 47 companies in the industry, just behind Puluo Pharmaceutical's revenue of 7.764 billion [2] - The company's net profit for the same period was 461 million, placing it fifth in the industry, lower than Zhejiang Pharmaceutical's 867 million and Puluo Pharmaceutical's 700 million [2] Group 2: Financial Ratios - As of Q3 2025, Nengte Technology's debt-to-asset ratio stood at 48.29%, higher than the industry average of 27.75% [3] - The company's gross profit margin was 1.52%, a decrease from 2.20% in the previous year, significantly below the industry average of 35.38% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 13.76% to 47,800, while the average number of circulating A-shares held per shareholder decreased by 18.02% to 45,400 [5]

Core Viewpoint - Hubei Nengte Technology Co., Ltd. is seeking to provide guarantees for its subsidiaries' applications for comprehensive credit lines from financial institutions to support their operational funding needs [3][4][12]. Group 1: Guarantee Overview - The company approved a proposal to provide guarantees for its wholly-owned subsidiary Nengte Technology Co., Ltd. to apply for a total of up to 43,000 million yuan in credit lines from CITIC Bank and China Bank [4][5][9]. - The guarantees include a maximum of 13,000 million yuan for trade credit and 30,000 million yuan for comprehensive credit, both with a one-year term [4][9]. - The company will also provide a guarantee of up to 10,000 million yuan for Nengte's application to China Bank for working capital loans and other financial services [5][9]. Group 2: Financial Status and Risk Assessment - The board of directors believes that Nengte has good creditworthiness, normal cash flow, and strong debt repayment ability, making the financing guarantees manageable and beneficial for business development [9][22]. - As of the announcement date, the total approved external guarantees by the company and its subsidiaries amount to 257,896 million yuan, with the company's guarantees to subsidiaries totaling 148,000 million yuan [10][23]. - The total external guarantees represent 73.65% of the company's audited net assets as of December 31, 2024, which is 350,171.72 million yuan [10][23]. Group 3: Additional Guarantee Proposals - The company also approved a proposal for its subsidiary Shanghai Plastic Mi to provide guarantees for its subsidiary Hubei Plastic Mi's applications for credit lines from Hubei Bank and Huaxia Bank [12][22]. - Hubei Plastic Mi is seeking a credit line of up to 10,000 million yuan from Hubei Bank and 3,500 million yuan from Huaxia Bank, both with a one-year term [12][19]. - The board of directors has authorized the representatives of the subsidiaries to negotiate and sign relevant legal documents regarding these credit applications [6][22].

Core Viewpoint - The company has disclosed its third-quarter financial report and announced plans for share repurchase and various financial guarantees for its subsidiaries [6][12][44]. Financial Data - The third-quarter financial report has not been audited [8]. - The company has repurchased a total of 34,236,100 shares, accounting for 1.38% of the total share capital [6]. - The company plans to repurchase shares using its own funds, with a total amount between RMB 30 million and RMB 50 million, at a price not exceeding RMB 4.70 per share [5]. Shareholder Information - The company will hold its sixth extraordinary general meeting on November 13, 2025, to discuss various proposals, including the cancellation of the supervisory board and amendments to the articles of association [19][35]. - The meeting will allow for both on-site and online voting, with specific registration and voting times outlined [36][41]. Board and Supervisory Meetings - The seventh board meeting was held on October 27, 2025, where several key proposals were approved, including the cancellation of the supervisory board and the third-quarter report [10][12][24]. - The supervisory board also convened on the same day, approving similar proposals and confirming the compliance of the third-quarter report with relevant regulations [25][26]. Financial Guarantees - The company has approved financial guarantees for its subsidiaries, including a comprehensive credit application for Nente Technology Co., Ltd. and Shanghai Plastic Information Technology Co., Ltd. [13][30][44]. - The total approved external guarantees amount to RMB 271.396 million, which is 77.50% of the company's audited net assets as of December 31, 2024 [44].

Core Viewpoint - Nengte Technology announced a board meeting held via telecommunication to discuss a proposal for its subsidiary to apply for comprehensive credit from financial institutions and for the company to provide guarantees [1] Group 1: Company Financials - For the first half of 2025, Nengte Technology's revenue composition was as follows: bulk trade accounted for 91.39%, pharmaceutical intermediates 8.39%, and park operations 0.22% [1] - As of the report date, Nengte Technology's market capitalization was 9.7 billion yuan [1]

Core Insights - Nengte Technology (002102) reported a revenue of 7.13 billion yuan for the first three quarters of 2025, a year-on-year decrease of 23.24%, while net profit attributable to shareholders reached 453 million yuan, an increase of 276.59% [1] - The company’s third-quarter revenue was 1.90 billion yuan, down 37.82% year-on-year, but net profit attributable to shareholders increased by 79.29% to 114 million yuan [1] - The vitamin E and pharmaceutical intermediates business of the wholly-owned subsidiary Nengte Technology Co., Ltd. performed well, contributing 626 million yuan to the company's profits, significantly boosting the overall performance for the first three quarters [1] Business Strategy - Since the acquisition by Jingzhou Urban Development Group in 2022, Nengte Technology has undergone a deep reform focusing on "streamlining and strengthening core business" [1] - The company officially changed its name to "Nengte Technology" in April 2024, marking a new phase in its strategic transformation [1] - The company is gradually divesting non-core assets to build a development framework centered on pharmaceuticals and vitamin E [1] Product Focus - Nengte Technology Co., Ltd. specializes in the research, production, and sales of pharmaceutical intermediates, with key products such as MK5 and R-1, which have significant cost advantages in global niche markets [1] - The company collaborates with Fortune 500 companies like DSM and China Merchants Group [1] Market Outlook - The vitamin E business is operated by Nengte Technology (Shishou) Co., Ltd. and the joint venture Yimante Health Industry (Jingzhou) Co., Ltd., with expectations of a significant price increase in vitamin E in the second half of 2024, leading to substantial growth in related business [2] - Nengte Technology aims to focus on fine chemical core business and innovate through process technology to develop internationally leading products that are lacking domestically, avoiding intense competition in traditional product areas [2] Asset Management - To concentrate resources on the fine chemical core business, Nengte Technology is actively disposing of or selling non-core assets [2] - On July 16, the company announced the transfer of 100% equity of its wholly-owned subsidiary, Shaanxi Ankang Shenqian Mining Co., Ltd., to Chongqing Hongmai Tianxia Industrial Development Group for 114 million yuan, which is expected to reduce the company's profit by approximately 49 million yuan in 2025 [2]

| | | 股东会议事规则 第一章 总则 第一条 为规范湖北能特科技股份有限公司（以下简称"公司"）行为，保 证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司章程指引》、 《上市公司股东会规则》、《深圳证券交易所股票上市规则》（以下简称"《上 市规则》"）、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等有关法律、行政法规、规范性文件和公司章程的规定，制定本规 则。 第二条 上市公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、公司章程及本规则的相关规定 召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临 ...